A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Kestrel Therapeutics, Inc.
Revolution Medicines, Inc.
Accent Therapeutics
Novartis
Elicio Therapeutics
UTC Therapeutics Inc.
Corvus Pharmaceuticals, Inc.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
MacroGenics
Abramson Cancer Center at Penn Medicine
Washington University School of Medicine
Alliance for Clinical Trials in Oncology
Memorial Sloan Kettering Cancer Center
Rutgers, The State University of New Jersey
City of Hope Medical Center
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Cancer Research UK
Roger Williams Medical Center
National Cancer Institute (NCI)
NYU Langone Health
Light Sciences LLC